We are committed to serving patients by developing innovative oral biologic medicines that have the potential to improve upon the efficacy, safety, and tolerability of biologic therapeutics in addition to providing them in the form of a convenient pill.
While biologics have revolutionized patient care for chronic conditions, they must be administered through inconvenient injections or intravenous infusions and often affect quality of life. Furthermore, systemically administered therapeutics are distributed broadly and unnecessarily affect multiple tissues in the body, not just the target tissue and organ; our GI-selective oral biologics are designed to address these issues.
We are highly focused on developing products for diseases with significant unmet medical need.
Ulcerative Colitis
Ulcerative colitis is a disease that causes inflammation and ulcers in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC usually starts between the ages of 15 and 30. The most common symptoms are pain in the abdomen and blood in diarrhea and other symptoms include anemia, severe tiredness, weight loss, loss of appetite, bleeding from the rectum, sores on the skin, and joint pain. Several types of drugs may help control UC, but there is still a need for better therapies to keep the disease in remission and improve patient outcomes.
Clinical Trials
AMT 101 – Ulcerative Colitis
Phase 2 clinical trial designed to evaluate the efficacy and safety of oral AMT-101 in adult subjects with moderate to severe ulcerative colitis
AMT 101 – Ulcerative Colitis
Phase 2 clinical trial designed to evaluate the efficacy and safety of oral AMT-101 in adult subjects with moderate to severe ulcerative colitis in combination with or without anti-TNF therapy
Resources
Pouchitis
Pouchitis is inflammation that occurs in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases. Many people with ulcerative colitis need to have their diseased colon removed and the bowel reconnected with a procedure called ileoanal anastomosis (J-pouch) surgery. In J-pouch surgery, surgeons use the end of the small intestine (ileum) to create a pouch shaped like the letter J that holds waste before it’s eliminated. Pouchitis can develop in 25-50% of the patients who have the procedure. It can be acute or chronic and is currently treated with antibiotics.
Clinical Trials
AMT 101 – Pouchitis
Phase 2 clinical trial designed to evaluate the efficacy and safety of oral AMT-101 in adult subjects with chronic pouchitis
Resources
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease, which means your immune system attacks your body’s own tissues. It causes pain, swelling, stiffness, and loss of function in your joints. It can affect any joint but is common in the wrist and fingers. RA can affect body parts besides joints, such as your eyes, mouth, and lungs. Treatments include drugs, lifestyle changes, and surgery. These can slow or stop joint damage and reduce pain and swelling, but additional therapies are needed.
Clinical Trials
AMT 101 – Rheumatoid Arthritis
Phase 2 clinical trial designed to evaluate the efficacy and safety of oral AMT-101 in adult subjects with moderate to severe rheumatoid arthritis with or without anti-TNF therapy
Resources
AMT’s Compassionate Use Policy
AMT is committed to developing safe and effective therapies and recognize that people living with these diseases may be interested in accessing our investigational therapies prior to regulatory approval. Our goal is to provide access to our investigational agents in the context of a clinical trial, where a complete understanding of the safety, tolerability, and efficacy of the product can be fully understood.
At this time, participation in one of our clinical trials is the only way to access our investigational therapies. If you have additional questions, please speak with your healthcare provider or contact AMT at info@appliedmt.com.
